Successful financing round for pharmaceutical company AMW

AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.

AMW GmbH (Arzneimittelwerk Warngau) has secured follow-up financing to advance the development and marketing process for its drug delivery systems. BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM Fund and IBG Beteiligungsgesellschaft are joining existing investors to inject up to seven million euro

The new funds will be used to market the existing product portfolio and develop a new technology for controlled drug delivery. AMW GmbH produces active ingredient implants and transdermal systems in the high-growth areas of oncology, pain therapy and neurology.

The current round of financing is intended to initially increase AMW GmbH’s capital by five million euro.

The old shareholders, which include the anchor investor SHS Gesellschaft für Beteiligungsmanagement, Bayern Kapital, KfW and AMW Managing Director Wilfried Fischer, have contributed a total of 1.4 million euros to the company, while in a 2nd closing three new shareholders, IBG Beteiligungsgesellschaft Sachsen-Anhalt with the venture capital fund II, the entrepreneur TUM fund and the BayBG Bayerische holding company, together provide 3.6 million euros. “This financing round enables us to push forward our marketing activities and bring our controllable transdermal technology into the approval process,” commented Dr. Wilfried Fischer on the capital grant. SHS Managing Director Bernhard Schirmers adds: “AS a company, AMW has now reached a stage in which the marketing of the promising product range is coming into focus. With the funds of this financing round, we are taking a big step into the market.”

Since its inception in 2008, AMW has evolved into a successful company with GMP production. The Warngau based company specializes in drug delivery systems – a very attractive segment of the pharmaceutical market, which is experiencing rapid growth around the globe. These systems deliver medication to patients using transdermal patches or subcutaneous implants. In addition to improved efficacy and tolerability, these systems provide simplified handling and dosing of medications.

Since its inception, AMW has developed an attractive product portfolio in the fields of oncology and neurology: one product is approved, three products are in the approval process and three other products are in advanced clinical development. With the funds of this financing round, AMW also wants to develop an active transdermal technology in which, in contrast to today’s passive technology, the drug delivery can be controlled and individually controlled to the needs of the patient.

BayBG investment manager Otto Hopfner lists further reasons for the investment: “The demand for patch and implant systems is experiencing dynamic growth for several years now and the segment currently amounts to approximately 30 billion US dollars. AMW is superbly positioned in this growth market and boasts numerous innovations.”

“We are impressed by the long-term track record and extensive process know-how of Dr. Wilfried Fischer and his team”, says Timo Komulainen, Managing Partner of the UnternehmerTUM Fund. “We will be actively supporting the planned setup of international sales for the new products”, Komulainen adds.

“We see a great medical need for drug implants and transdermal systems and a wide range of benefits especially in the areas of oncology, pain therapy and neurology”, explains Martin Laub, Investment Manager at IBG, and adds, “With both its existing productportfolio and the new technologies to be developed, AMW as a whole is in an excellent position to implement its targeted growth strategy.

Endomedica GmbH, a 100% subsidiary of AMW headquartered in Halle (Saale), will take on an essential role in this regard in the future. In addition to marketing its own existing product portfolio, it will be responsible for driving and coordinating the technical and clinical development of innovative, controllable transdermal technologies in partnership with scientific institutions in the region

About AMW GmbH

AMW GmbH is a pharmaceuticals company, which specializes in innovative drug delivery systems. AWM’s products deliver medication to patients using transdermal patches or subcutaneous implants. The company was established by Dr. Wilfried Fischer in 2008 and develops treatment solutions in the areas of oncology, neurology, dermatology and pain therapy. AMW is located in Warngau in the Upper Bavaria region of Germany.

About BayBG:

Through its investments, BayBG is currently strengthening the capital base of 500 Bavarian medium-sized businesses. The BayBG is thus the Bavarian market leader among medium-sized enterprise-oriented investment companies. Through its commitment, the BayBG enables the companies to realize expansion and innovation plans, make corporate succession plans as well as optimize the capital structure and implement of turn-around measures.

About the UnternehmerTUM Fund

EntrepreneurTUM-Fonds, Garching (Munich), invests in young technology companies in the fields of information and communication technology, medical technology and cleantech throughout Germany. The portfolio companies benefit from the many years of experience of entrepreneurs in building up young companies. EntrepreneurTUM Fund has its own industry experts and a unique network in the industry and to other venture capital investors.

EIF, ERP and CIP: UnternehmerTUM Fund is supported by the European Investment Fund (EIF), by the European Union through the Competitiveness and Innovation Framework Program (CIP), and by the ERP-EIF and LfA-EIF funds of funds.

About IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH:

The IBG BeteiligungsgesellschaftSaxony-Anhalt mbH, based in Magdeburg, manages the three investment funds IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG and the IBG Innovationsfonds GmbH & Co. KG. The funds invest primarily in technology-based startup companies in Saxony-Anhalt. Investments are preferably made in the fields of technology, life science, new materials, new energy, microsystems technology, software engineering and process engineering / mechanical engineering